BRAF V600 Mutant Melanoma

1. Disease Information

Overview

BRAF V600 Mutant Melanoma is a molecularly defined subtype of cutaneous malignant melanoma characterized by somatic gain-of-function mutations at codon 600 of the BRAF gene (7q34). BRAF is a serine/threonine protein kinase in the MAPK/ERK signaling pathway that regulates cell proliferation, differentiation, and survival. The V600E mutation (a thymine-to-adenine transversion resulting in valine-to-glutamic acid substitution) accounts for the vast majority of cases and produces a constitutively active kinase domain that drives oncogenesis independent of upstream RAS activation (PMID: 39961465).

As noted by Paluncic et al., "40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E)" (PMID: 33801689). Among BRAF V600 mutations, the distribution is: V600E (79%), V600K (12%), V600R (5%), and V600M (4%) (PMID: 22536370).

Key Identifiers

Synonyms and Alternative Names

• BRAF V600E-mutated melanoma
• BRAF-mutant melanoma
• BRAF V600E/K melanoma
• V600E-positive melanoma
• Melanoma with activating BRAF mutation
• MAPK-driven melanoma (when referring to mechanism)

Information Sources

This report is derived from aggregated disease-level resources including published clinical trials, genomic databases (COSMIC, ClinVar, TCGA), epidemiological registries (SEER, GLOBOCAN), and primary research literature (PubMed). Individual patient-level data is referenced from landmark clinical trials (COMBI-d, COLUMBUS, IMspire150) and real-world registries (ADMIRE, Dutch Melanoma Treatment Registry).

2. Etiology

Disease Causal Factors

BRAF V600 Mutant Melanoma arises through a multi-step oncogenic process involving both genetic and environmental factors:

Somatic genetic origin: The BRAF V600E mutation is a somatic (acquired) missense mutation arising in melanocytes. It is not inherited in the germline but occurs during the lifetime of the individual. The mutation results in constitutive activation of the BRAF kinase, which "results in a constitutively active kinase domain, leading to dysregulated downstream signaling independent of extracellular stimuli. This sustained activation promotes cell proliferation, survival, angiogenesis, and hallmark features of the cancer cells" (PMID: 39961465).

UV radiation as initiating factor: Ultraviolet radiation, particularly UVB (280–320 nm), is the primary environmental mutagen. UV radiation induces DNA damage in melanocytes, including the characteristic thymine dimer mutations. The BRAF V600E mutation itself (T1799A) is not a classic UV signature mutation (C>T at dipyrimidine sites), suggesting that UV may act indirectly through mutagenic stress, oxidative damage, or proliferative stimulation rather than direct photoproduct formation (PMID: 27221301).

Risk Factors

Genetic Risk Factors

• BRAF V600E somatic mutation (driver): Present in 40–50% of cutaneous melanomas; constitutive MAPK activation
• CDKN2A (p16INK4A) germline mutations: High-penetrance melanoma susceptibility gene; loss of cell cycle control at G1/S checkpoint
• CDK4 mutations: Rare high-penetrance susceptibility gene
• MC1R variants: Red hair color variants (R151C, R160W, D294H) associated with fair skin, poor tanning, and increased melanoma risk
• PTEN loss: Frequently co-occurs with BRAF V600E (seen in ~40% of BRAF-mutant melanomas); synergistic oncogenic effect through PI3K/AKT pathway activation
• TERT promoter mutations: Common co-occurring mutations promoting telomere maintenance
• Co-occurring NRAS mutations: Mutually exclusive with BRAF V600E in primary tumors but may arise as resistance mutations

Environmental Risk Factors

Associations with BRAF mutation were characterized by Colombino et al.: "Associations with BRAF mutation were as follows: male gender [odds ratio (OR) = 2.4], younger age (OR = 2.7), superficial spreading (OR = 15.6) and nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)" (PMID: 25357015).

• Intermittent UV exposure: Strong association (OR = 4.6) vs. chronic sun exposure
• Indoor tanning: "BRAF V600E genotype was more prevalent in ever-users than in nonusers (42.9% vs 28.3%, two-sided P = .04) and higher in ever-users who initiated indoor tanning prior to age 25 years compared with age 25 years or older (62.2% vs 31.1%, two-sided P = .003)" (PMID: 30923800)
• Sunburn history: Blistering sunburns associated with increased absolute mutation incidence (1.67 vs 1.16 mutations/patient, P = 0.028) (PMID: 32445930)
• Fair skin phenotype: Fitzpatrick skin types I and II
• High nevus count: Multiple dysplastic nevi as a risk factor
• Male sex: OR = 2.4 for BRAF mutation
• Younger age: OR = 2.7 for BRAF mutation (median age younger than BRAF wild-type)
• Residence in high-UV areas: OR = 5.54 (95% CI 1.19–25.8) for residing in states with UV index ≥7 vs ≤5 at age 30 (PMID: 25048604)

Possible Non-Traditional Risk Factors

• Hexavalent chromium exposure: Epidemiological data suggest heavy metal exposure may contribute; UV accounts for only 40–50% of attributable melanoma risk (PMID: 21253789)

Protective Factors

Genetic Protective Factors

• MC1R wild-type: Associated with darker skin pigmentation and improved UV protection
• Certain HLA genotypes: Associated with improved immune surveillance
• High MITF expression: May maintain melanocyte differentiation programs

Environmental Protective Factors

• Sun protection behaviors: Use of sunscreen (high SPF), protective clothing, avoidance of midday sun
• Avoidance of indoor tanning, especially before age 25
• Regular skin self-examination and professional screening
• Dietary factors: Some evidence for vitamin D, antioxidants, though data are inconclusive

Gene–Environment Interactions

The BRAF V600E mutation appears to arise preferentially in the context of intermittent rather than chronic UV exposure, explaining its association with trunk melanomas (usually covered, intermittently exposed) in younger patients. The B-RafV600E mutation was detected in 85% of trunk melanomas in indoor workers versus 47% in outdoor workers (P = 0.03), indicating that "the B-RafV600E mutation detected in melanoma is not associated with a chronic exposure to the sun" but rather with recreational/intermittent exposure (PMID: 24424406). MC1R variants may further modify risk by impairing DNA repair capacity in the setting of UV exposure, creating a synergistic effect.

3. Phenotypes

Clinical Signs and Symptoms

Phenotype Characteristics Specific to BRAF V600 Mutant Melanoma

• Age of onset: Younger than BRAF wild-type melanomas (OR = 2.7 for younger age) (PMID: 25357015)
• Histological subtypes: Strongly associated with superficial spreading melanoma (OR = 15.6) and nodular melanoma (OR = 9.5)
• Anatomical predilection: Trunk localization (OR = 6.3); less common on chronically sun-damaged skin (head/neck)
• Mitotic activity: BRAF-mutated melanomas tend to be more mitotically active (PMID: 28424234)

Quality of Life Impact

Advanced BRAF V600 mutant melanoma significantly impacts quality of life through: - Physical symptoms of metastatic disease (pain, fatigue, neurological deficits from brain metastases) - Psychological distress from cancer diagnosis and treatment - Treatment-related side effects (pyrexia, arthralgia, skin toxicities from targeted therapy; immune-related adverse events from immunotherapy) - Functional impairment from disease complications

4. Genetic/Molecular Information

Causal Gene

BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) - HGNC ID: HGNC:1097 - NCBI Gene ID: 673 - OMIM: 164757 - Chromosomal location: 7q34 - UniProt: P15056 - Protein*: 766 amino acid serine/threonine kinase

Pathogenic Variants

Source for variant distribution: "Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively" (PMID: 22536370).

Variant classification: All V600 mutations listed are classified as pathogenic (oncogenic driver) in ClinVar and COSMIC.

Somatic origin: These mutations are somatic, not germline. They are acquired during the individual's lifetime and are not present in the germline. COSMIC reports BRAF V600E as one of the most frequently mutated positions across all human cancers.

V600K demographics: V600K was detected in 23% of men older than 60, compared with 6% in women older than 60 and 2% in both sexes younger than 60 (P < .001), suggesting age and sex-specific patterns (PMID: 25456393).

Modifier Genes and Co-occurring Alterations

• PTEN (10q23.31): Loss-of-function mutations or deletions co-occur in ~40% of BRAF V600E melanomas; activates PI3K/AKT pathway synergistically
• CDKN2A (9p21.3): Homozygous deletion or inactivating mutation; loss of p16INK4A and p14ARF tumor suppressors
• TP53 (17p13.1): Mutations less common in melanoma than other cancers but contribute to genomic instability
• TERT promoter (5p15.33): Activating promoter mutations (C228T, C250T) frequent in BRAF-mutant melanoma
• APC, CTNNB1: Occasional Wnt pathway alterations
• NF1: Generally mutually exclusive with BRAF V600E but defines a separate molecular subtype

Epigenetic Information

• Global DNA hypomethylation: Common in melanoma progression
• Promoter hypermethylation: Silencing of tumor suppressors (RASSF1A, MGMT, DAPK)
• BRAF V600E suppresses MITF: Leading to reduced melanocyte differentiation gene expression
• Histone modifications: H3K27me3 changes associated with melanoma progression; EZH2 overexpression
• CpG island methylator phenotype (CIMP): Associated with BRAF V600E in colorectal cancer; less well-characterized in melanoma

Chromosomal Abnormalities

• Chromosome 7 gain: Frequently observed (location of BRAF); may increase BRAF dosage
• Chromosome 10 loss: Contains PTEN; frequently deleted in BRAF-mutant melanomas
• 9p21 deletion: Loss of CDKN2A locus
• 6p gain: Common in melanoma
• Mutant allele-specific imbalance (MASI): BRAF V600E MASI predominantly present in distant organ metastases (79% vs 27% in LN metastases vs 13% in primary tumors, P < .001) (PMID: 25456393)

5. Environmental Information

Environmental Factors

• Ultraviolet radiation (UVA/UVB): The primary environmental carcinogen. UVB (280–320 nm) directly damages DNA; UVA (320–400 nm) induces oxidative damage. "About 95% of ultraviolet A (UVA) and 5% of UVB reach the Earth's surface" (PMID: 27221301)
• CHEBI term: CHEBI:27460 (ultraviolet radiation — as a physical agent)
• Hexavalent chromium: Proposed as a co-carcinogen; "UV light exposure accounts for only 40-50% of the attributable risk for cutaneous melanoma" (PMID: 21253789)

Lifestyle Factors

• Indoor tanning: Strong risk factor; BRAF V600E prevalence of 62.2% in users who started before age 25 (PMID: 30923800)
• Intermittent recreational sun exposure: Stronger association with BRAF mutation than chronic occupational exposure (OR = 4.6) (PMID: 25357015)
• Sunburn history: Particularly childhood/adolescent blistering sunburns

Infectious Agents

• Beta-genus HPV: May accelerate keratinocyte carcinogenesis during BRAF inhibitor therapy. β-HPV-17, HPV-38, HPV-111 were most frequently isolated in BRAFi-associated cutaneous squamous cell carcinomas (PMID: 25724524). This is relevant to treatment-related secondary malignancies rather than melanoma etiology itself.

6. Mechanism / Pathophysiology

Molecular Pathways

RAS–RAF–MEK–ERK (MAPK) Pathway (Primary)

The central oncogenic pathway in BRAF V600 melanoma. The BRAF V600E mutation produces a constitutively active kinase that signals as a monomer (unlike wild-type BRAF which requires dimerization). This leads to sustained MEK1/2 and ERK1/2 phosphorylation, driving:

1. Cell proliferation: Transcriptional activation of cyclin D1, c-Myc, and other cell cycle promoters
2. Survival: Suppression of pro-apoptotic BIM, BAD; upregulation of anti-apoptotic MCL-1, BCL-2
3. Angiogenesis: Upregulation of VEGF and other pro-angiogenic factors
4. Invasion and metastasis: Induction of matrix metalloproteinases (MMPs), epithelial-mesenchymal transition (EMT)

KEGG pathway: hsa04010 (MAPK signaling pathway) Reactome: R-HSA-5673001 (RAF/MAP kinase cascade)

PI3K/AKT/mTOR Pathway (Cooperating)

Frequently co-activated through PTEN loss. Synergizes with MAPK pathway to promote survival and metabolic adaptation. Important in resistance to BRAF inhibitors.

KEGG pathway: hsa04151 (PI3K-Akt signaling pathway)

Wnt/β-Catenin Pathway

Contributes to melanoma cell survival, immune evasion, and resistance to immunotherapy.

Cellular Processes

• Uncontrolled proliferation: GO:0008283 (cell population proliferation)
• Evasion of apoptosis: GO:0043066 (negative regulation of apoptotic process)
• Metabolic reprogramming: GO:0006096 (glycolytic process); GO:0006119 (oxidative phosphorylation)
• Angiogenesis: GO:0001525 (angiogenesis)
• Immune evasion: GO:0002837 (negative regulation of immune response to tumor cell)
• Cell migration/invasion: GO:0016477 (cell migration)

Protein Dysfunction

The BRAF V600E mutation resides in the activation segment of the kinase domain. The valine-to-glutamic acid substitution mimics the phosphorylation that normally activates the kinase, locking it in a constitutively active conformation. Wild-type BRAF kinase activity is ~70-fold lower than V600E mutant BRAF. The mutant signals as a monomer, unlike wild-type BRAF which requires RAS-dependent dimerization, explaining its RAS-independence.

UniProt: P15056 (BRAF_HUMAN) PDB: 1UWH (BRAF kinase domain), 3OG7 (BRAF V600E with vemurafenib)

Metabolic Changes

BRAF V600E drives a profound metabolic reprogramming:

"BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation" (PMID: 38972133).

The mechanistic basis: "BRAF(V600E) acts to suppress expression of the melanocyte master regulator microphthalmia-associated transcription factor (MITF) and the mitochondrial biogenesis coactivator PGC1α. Accordingly, therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS through increased MITF-PGC1α levels" (PMID: 24610826).

This metabolic plasticity is a key resistance mechanism: upon BRAF inhibitor treatment, cells shift from glycolysis to oxidative phosphorylation (OXPHOS), with increased glutamine dependence and mitochondrial biogenesis. NSAIDs (diclofenac, lumiracoxib) can counteract this metabolic reprogramming and synergize with BRAF inhibitors by preventing the shift to OXPHOS (PMID: 30481565).

KEGG pathways: hsa00010 (Glycolysis/Gluconeogenesis); hsa00190 (Oxidative phosphorylation) HMDB: HMDB0000190 (L-Lactic acid — elevated in glycolytic tumors)

Immune System Involvement

BRAF V600E melanoma has a complex relationship with the immune system:

• Tumor immune evasion: BRAF V600E upregulates immunosuppressive cytokines (IL-6, IL-10, VEGF) and downregulates MHC class I expression
• PD-L1 expression: Upregulated in BRAF-mutant tumors, particularly upon BRAF inhibitor treatment
• T cell infiltration: BRAF inhibition increases intratumoral CD8+ T cell infiltrate, suggesting immune activation (PMID: 24903021)
• B cell involvement: Tumor-infiltrating B cells may serve as a predictive biomarker; higher B cell signatures associated with better outcomes on dabrafenib + trametinib (PMID: 34108180)
• Immune-related adverse events as biomarker: Vitiligo, panniculitis, and other immune-related skin lesions during BRAF/MEK inhibitor treatment predict better outcomes (HR 0.19 for disease progression, P = 0.043) (PMID: 30939167); immune AEs associated with mPFS of 42.8 months vs 6.1 months without (HR 0.22, P = 0.002) (PMID: 30096703)

Tissue Damage Mechanisms

• Local invasion: Vertical growth phase melanoma invades dermis and subcutaneous tissue
• Lymphatic spread: Regional lymph node metastasis (stage III)
• Hematogenous spread: Distant metastasis to lung, liver, brain, bone, skin (stage IV)
• Melanoma-induced stromal remodeling: Melanoma exosomes reprogram stromal fibroblasts via exosomal miR-155 and miR-210, increasing aerobic glycolysis and extracellular acidification to create a pre-metastatic niche (PMID: 30150674)

Resistance Mechanisms

Acquired resistance to BRAF inhibitors is multifactorial:

"Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations" (PMID: 23569304).

Key resistance mechanisms include: 1. MAPK reactivation: Secondary NRAS mutations, MEK mutations, BRAF amplification, BRAF splice variants 2. Alternative pathway activation: PI3K/AKT, focal adhesion kinase (FAK) signaling 3. Metabolic reprogramming: Shift from glycolysis to OXPHOS 4. Phenotype switching: Transition from proliferative to invasive state 5. Microenvironment remodeling: Stromal cell-mediated resistance 6. COP1/DET1 mutations: Acquired after BRAF inhibitor treatment, affecting oncogenic transcriptome regulation (PMID: 40643496)

Molecular Profiling

Transcriptomics

• BRAF V600E melanomas show distinct gene expression profiles with upregulation of MAPK target genes
• Three tumor subgroups identified by gene expression clustering including an "immune" subgroup associated with improved survival (PMID: 41537702)
• High IFNγ gene signature scores and cytolytic scores predict better response to encorafenib + binimetinib

Proteomics

• Plasma proteome alterations detectable by MAPKi treatment (PMID: 34246984)
• p-ERK immunohistochemistry serves as a readout of MAPK pathway activity

Liquid Biopsy / Circulating Tumor DNA

• BRAF V600 ctDNA detectable by droplet digital PCR (ddPCR) in 93% of pretreatment samples
• Baseline ctDNA positivity rate was 13% in stage III resected disease
• ctDNA detection associated with worse recurrence-free survival (median 3.71 vs 24.41 months in placebo; HR 2.91, P < 0.0001) (PMID: 40250457)
• On-treatment ctDNA clearance predicts improved outcomes across all treatment arms (PMID: 33587894; PMID: 41537702)

7. Anatomical Structures Affected

Organ Level

Primary organ: Skin (UBERON:0002097) - Cutaneous melanoma arises from epidermal melanocytes

Secondary organ involvement (sites of metastasis): - Lymph nodes (UBERON:0000029): Regional spread; sentinel lymph node most commonly affected - Lung (UBERON:0002048): Most common site of distant metastasis - Liver (UBERON:0002107): Second most common distant site - Brain (UBERON:0000955): ~32% of advanced cases have brain metastases at presentation (PMID: 34243078) - Bone (UBERON:0002481): Common distant metastatic site - Distant skin/subcutaneous tissue: Transit metastases

Body systems: Integumentary (primary), lymphatic, respiratory, hepatobiliary, nervous, musculoskeletal

Tissue and Cell Level

• Melanocytes (CL:0000148): Cell of origin; neural crest-derived pigment cells in the basal epidermis
• Keratinocytes (CL:0000312): Surrounding cells affected by paracrine signaling
• Tumor-infiltrating lymphocytes: CD8+ T cells (CL:0000625), CD4+ T cells (CL:0000624), B cells (CL:0000236), regulatory T cells (CL:0000815)
• Dermal fibroblasts (CL:0000057): Reprogrammed by melanoma exosomes
• Endothelial cells (CL:0000115): Involved in tumor angiogenesis

Subcellular Level

• Cytoplasm/cytosol (GO:0005829): Location of BRAF kinase activity and MAPK cascade
• Cell membrane (GO:0005886): RAS activation, receptor tyrosine kinase signaling
• Nucleus (GO:0005634): ERK-mediated transcriptional activation
• Mitochondria (GO:0005739): Site of metabolic reprogramming (OXPHOS vs glycolysis)
• Lysosomes (GO:0005764): Autophagy involvement in resistance

Localization

• Primary site predilection: Trunk (UBERON:0002100) — OR = 6.3 for BRAF-mutant melanoma
• Intermittently sun-exposed skin: Back, chest, abdomen
• Less common in chronically sun-damaged sites: Head and neck (more associated with NRAS or NF1 mutations)
• Lateralization: Unilateral; no specific laterality preference

8. Temporal Development

Onset

• Typical age: Adult-onset, but younger than BRAF wild-type melanomas. Median age ~50–55 years for BRAF-mutant vs ~60–65 for wild-type. BRAF V600K patients tend to be older (>60 years)
• Onset pattern: Insidious; typically progresses from a pre-existing nevus or arises de novo over months to years
• Precursor lesions: Dysplastic nevi; BRAF V600E is found in ~80% of benign nevi (necessary but not sufficient for melanoma development)

Progression

AJCC Staging System (8th Edition):

• Progression rate: Variable; can be rapid (weeks–months for nodular melanoma) or indolent (years for superficial spreading)
• Disease course: Progressive without treatment; potential for long-term remission with modern therapy
• Duration: Chronic; lifelong surveillance required even after complete response

Patterns

• Remission patterns: Treatment-induced remissions with BRAF/MEK inhibitors (median duration ~9–12 months); more durable remissions with immunotherapy (years)
• Critical periods:
• Early intervention after diagnosis significantly impacts survival
• Window of opportunity for adjuvant therapy in resected stage III disease
• First 3 years post-treatment: highest risk of recurrence with targeted therapy
• Brain metastasis development: critical period requiring prompt intervention

9. Inheritance and Population

Epidemiology

Global melanoma burden (all subtypes): "A worldwide total of 325,000 new melanoma cases (174,000 males, 151,000 females) and 57,000 deaths (32,000 males, 25,000 females) was estimated for 2020" (PMID: 35353115). "Cutaneous melanoma causes 55,500 deaths annually" and accounts for 90% of skin cancer mortality (PMID: 30238891).

BRAF V600 mutant melanoma specifically: - Represents ~40–50% of cutaneous melanomas - Estimated ~130,000–162,500 new BRAF V600 mutant melanoma cases worldwide annually - Highest absolute numbers in populations with high melanoma incidence (Australia/New Zealand, Europe, North America)

Incidence by region (all melanoma): - Australia/New Zealand: Males 42/100,000; Females 31/100,000 (highest worldwide) - Western Europe: ~19/100,000 - North America: Males 18, Females 14/100,000 - Africa and Asia: <1/100,000

Genetic Etiology Considerations

• Not a Mendelian inherited disease: BRAF V600 mutations are somatic
• Inheritance pattern: Multifactorial/polygenic predisposition to melanoma; the specific BRAF mutation is acquired somatically
• Familial melanoma syndromes: CDKN2A, CDK4, BAP1, POT1 germline mutations increase melanoma susceptibility but do not guarantee BRAF mutation status
• Penetrance: Not applicable to the somatic BRAF mutation itself; familial melanoma gene penetrance varies (CDKN2A: 58–92% by age 80)

Population Demographics

• Sex ratio: Male predominance (OR = 2.4 for BRAF mutation); male:female ~1.15:1 for melanoma overall
• Ethnic/racial distribution: Predominantly affects fair-skinned populations of European descent; rare in African, Asian, and Hispanic populations
• Age distribution: BRAF-mutant melanomas are younger at diagnosis than BRAF wild-type; V600K specifically more common in older males (>60 years)
• Geographic distribution: Higher prevalence in regions with high UV exposure and fair-skinned populations (Australia, Northern Europe, North America)
• BRAF mutation rate varies by melanoma subtype: ~50% cutaneous, ~10–15% acral/mucosal (PMID: 37016119)

10. Diagnostics

Clinical Tests

Laboratory Tests

• Serum lactate dehydrogenase (LDH): Prognostic biomarker; elevated LDH indicates high tumor burden and is associated with shorter PFS and OS
• Complete blood count: Baseline and monitoring; neutrophil/lymphocyte ratio has prognostic value
• Liver function tests: Monitoring for hepatic metastases and drug hepatotoxicity
• Renal function: Monitoring required due to nephrotoxicity of BRAF inhibitors, especially vemurafenib (PMID: 26182194)
• Serum S100B: Tumor marker for melanoma staging and monitoring

Biomarkers

• BRAF V600 mutation status: Essential companion diagnostic; determines eligibility for targeted therapy
• Circulating tumor DNA (ctDNA): BRAF V600 ctDNA by ddPCR — prognostic and predictive biomarker; detectable in 93% of pretreatment metastatic samples (PMID: 33587894); ctDNA clearance at early timepoints predicts improved survival (PMID: 40250457)
• PD-L1 expression: Relevant for immunotherapy decisions
• Tumor mutational burden (TMB): Higher TMB associated with better response to combination targeted therapy (PMID: 41537702)
• IFNγ gene signature: Immune microenvironment biomarker

Imaging

• Dermoscopy: Initial evaluation of suspicious lesions
• CT (chest/abdomen/pelvis): Staging for distant metastases
• PET/CT: Whole-body staging, recommended from stage IIB/C
• MRI brain: Mandatory for staging; brain metastases present in ~32% of advanced cases
• Ultrasound: Regional lymph node assessment; recommended from stage IB

Biopsy/Pathology

• Excisional biopsy: Gold standard for primary diagnosis; provides Breslow depth, mitotic rate, ulceration status
• Histopathology: Superficial spreading and nodular subtypes most common in BRAF-mutant melanoma
• Immunohistochemistry: Anti-BRAF V600E VE1 clone antibody — sensitivity 86.1%, specificity 96.9%, concordance with PCR 95.1% (PMID: 28424234)
• Sentinel lymph node biopsy: Staging procedure for melanomas ≥0.8 mm with risk factors or ≥1.0 mm (PMID: 35623961)

Genetic Testing

Recommended Testing Approach

BRAF mutation testing is recommended for all patients with stage IIB/C or higher melanoma, and is mandatory before initiating BRAF/MEK inhibitor therapy (PMID: 39700658).

Testing Methods

Quality assurance: French national EQA achieved false response rate of only 4.8% across 46 laboratories, with improvement from 22 to 12 days turnaround over 6 months (PMID: 24119386).

Clinical Criteria

• AJCC 8th Edition staging: Standard staging system
• Breslow depth: Most important histological prognostic factor
• Ulceration status: Independent prognostic factor
• Mitotic rate: Prognostic significance
• BRAF V600 mutation status: Determines targeted therapy eligibility

Differential Diagnosis

• BRAF wild-type melanoma (NRAS, NF1, or triple wild-type subtypes)
• Atypical/dysplastic nevus
• Spitz nevus (may harbor BRAF fusions but not typically V600E)
• Blue nevus
• Melanoma in situ
• Pigmented basal cell carcinoma

11. Outcome/Prognosis

Survival and Mortality

Metastatic BRAF V600 mutant melanoma (with modern therapy):

Source: "3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively" (PMID: 28475671).

Real-world data: ORR 57.4% for combined BRAFi+MEKi vs 39.8% BRAFi monotherapy; median PFS 9.2 months; median OS 22.6 months for first-line combination (PMID: 34064013).

BRAF mutation level as prognostic factor: High BRAF V600 mutation level (>0.44) associated with worse PFS and OS on multivariate analysis (P = 0.02 for both) (PMID: 39508497).

Prognostic Factors

Favorable: - Normal LDH - ECOG PS 0 - <3 metastatic sites - No brain metastases - Immune-related adverse events during treatment (mPFS 42.8 vs 6.1 months; HR 0.22, P = 0.002) (PMID: 30096703) - ctDNA clearance on treatment - High tumor immune infiltration and TMB

Unfavorable: - Elevated LDH - ECOG PS ≥1 - ≥3 metastatic sites - Brain metastases (introduced as major prognostic factor in real-world setting) (PMID: 34243078) - High BRAF V600 mutation level - Detectable ctDNA at baseline and on treatment

Prognostic Biomarkers

• ctDNA: Strongest blood-based prognostic biomarker; "Baseline ctDNA was more strongly associated with survival outcomes than IFNG gene expression or tumour mutational burden" (PMID: 40250457)
• LDH: Standard serum biomarker
• S100B: Serum protein biomarker
• CD8+ TILs: Higher density associated with better outcomes
• B cell signatures: Potential predictive biomarker for targeted therapy (PMID: 34108180)

12. Treatment

Pharmacotherapy

FDA-Approved Targeted Therapy Combinations

MAXO terms: MAXO:0001084 (targeted molecular therapy); MAXO:0000058 (pharmacotherapy)

CHEBI terms: Vemurafenib (CHEBI:63637), Dabrafenib (CHEBI:75045), Trametinib (CHEBI:75998), Encorafenib (CHEBI:145372), Binimetinib (CHEBI:145371), Cobimetinib (CHEBI:145373)

Acceptability and Safety

In a network meta-analysis: "the combination of dabrafenib and trametinib is the preferred combination therapy" for BRAF V600-mutant melanoma, with better acceptability than vemurafenib + cobimetinib (RR for any-grade AEs: 0.94; CrI: 0.89–0.98) (PMID: 35530323).

Common adverse events (vemurafenib): arthralgia (37%), alopecia (25%), hyperkeratosis (23%); most common grade 3/4: cutaneous SCC (8%) and keratoacanthoma (8%) (PMID: 28501764).

Nephrotoxicity: Vemurafenib more nephrotoxic than dabrafenib; 132 cases of AKI reported with vemurafenib vs 13 with dabrafenib; predominantly tubular interstitial injury (PMID: 26182194).

Phototoxicity: Vemurafenib causes clinical photosensitivity (PMID: 24154489).

Immunotherapy

MAXO terms: MAXO:0001085 (immune checkpoint inhibitor therapy)

Treatment Sequencing

European guidelines recommend: "For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy" (PMID: 35623961).

Adjuvant Therapy

For resected stage III disease: - Dabrafenib + Trametinib: Approved adjuvant; 3-year RFS ~60% in COMBI-AD - Anti-PD-1 (nivolumab, pembrolizumab): Alternative adjuvant option regardless of BRAF status - Real-world data from China: D+T significantly superior to observation (P = 0.002) and potentially superior to anti-PD-1 monotherapy (P = 0.032) for RFS in BRAF-mutant stage III melanoma (PMID: 37016119)

Brain Metastases

Encorafenib + binimetinib achieves brain metastasis response rate >60% (PMID: 40503961). Real-world data shows median PFS of 5.5 months and OS of 11.9 months for BRAF V600-mutant melanoma with brain metastases (PMID: 40411977). Stereotactic radiosurgery combined with immunotherapy achieves the highest OS rates in brain metastases; BRAF mutation appears to be a favorable prognostic factor (PMID: 30739835).

Surgical Interventions

• Wide local excision: Primary treatment; 1–2 cm margins based on Breslow depth
• Sentinel lymph node biopsy: Staging procedure for ≥0.8 mm with risk factors
• Complete lymph node dissection: For sentinel node-positive disease (increasingly replaced by adjuvant systemic therapy)
• Metastasectomy: For oligometastatic disease amenable to complete resection

MAXO terms: MAXO:0000004 (surgical procedure); MAXO:0000011 (excision)

Experimental Therapies and Novel Approaches

• PHI-501: Dual RAF/DDR1/2 inhibitor overcomes MAPK resistance (PMID: 41935307)
• Avutometinib (RAF-MEK clamp) + FAK inhibitors: Overcomes resistance to BRAFi+MEKi and immunotherapy (PMID: 40020669)
• Metabolic targeting: NSAIDs (diclofenac, lumiracoxib) + BRAF inhibitors delay resistance (PMID: 30481565)
• DCA (dichloroacetate) + elesclomol: Targeting metabolic reprogramming, effective even in vemurafenib-resistant cells (PMID: 22865452)
• Gene-edited stem cell therapy: Allogeneic twin stem cell system for brain metastatic melanoma (PMID: 37256936)

Chemotherapy

Weekly carboplatin + paclitaxel remains a palliative option after immunotherapy failure: median PFS 3.25 months, OS 7.69 months (PMID: 39354418).

13. Prevention

Primary Prevention

• UV radiation avoidance: Limiting sun exposure, especially during peak hours (10 AM – 4 PM)
• Sunscreen use: Broad-spectrum SPF 30+ recommended
• Protective clothing: Hats, long sleeves, UV-protective fabrics
• Avoidance of indoor tanning: Especially before age 25 (62.2% BRAF V600E prevalence in early initiators vs 31.1%, P = .003) (PMID: 30923800)
• Education: USPSTF recommends counseling on UV exposure minimization, especially for patients aged 6 months to 24 years (PMID: 39418569)
• Public health campaigns: Beach-based campaigns can identify high-risk individuals; one campaign found 8.1% suspicious skin cancer lesions and 2.9% possible melanomas among 407 beachgoers (PMID: 25069660)

MAXO terms: MAXO:0000118 (sun protection counseling); MAXO:0000002 (preventive care)

Secondary Prevention (Screening and Early Detection)

• Skin self-examination: ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) and "ugly duckling" sign
• Dermoscopy: Non-invasive tool enhancing clinical diagnosis; superior to naked-eye examination (PMID: 20806172)
• Total body photography and digital dermoscopy: For high-risk patients to detect early changes
• Confocal reflectance microscopy: Improves clinical diagnosis in special cases (PMID: 39700658)
• Risk stratification: Identifying individuals with multiple nevi, family history, fair skin for targeted screening

Tertiary Prevention

• Adjuvant therapy: Dabrafenib + trametinib or anti-PD-1 for resected stage III disease to prevent recurrence
• Surveillance protocols: Stage-based follow-up with imaging and clinical examination
• ctDNA monitoring: Emerging tool for minimal residual disease detection; patients with favorable ctDNA kinetics (durable undetectable) have markedly better outcomes (PMID: 40250457)

Genetic Counseling

• For familial melanoma kindreds (CDKN2A, CDK4, BAP1 mutations)
• BRAF V600E itself is somatic and does not require genetic counseling for family members
• Identification of mole-prone phenotype in adolescents may facilitate early intervention (PMID: 28593303)

14. Other Species / Natural Disease

Taxonomy

BRAF mutations and melanoma occur across species:

Natural Disease in Animals

• Dogs: Oral and cutaneous melanoma occurs naturally; BRAF mutations are rare but reported. Canine melanoma serves as a comparative oncology model
• Horses: Grey horses develop melanoma with high frequency (>80% of grey horses >15 years); pathogenesis involves STX17 duplication rather than BRAF mutations
• Fish: Xiphophorus (swordtail-platyfish) hybrids develop melanoma driven by xmrk oncogene, not BRAF

Comparative Biology

• The RAS-RAF-MEK-ERK pathway is highly conserved across vertebrates
• BRAF V600E can drive melanocyte transformation in zebrafish, demonstrating evolutionary conservation of the oncogenic mechanism
• Zebrafish BRAF V600E melanomas "show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers" (PMID: 24148783)

15. Model Organisms

Mouse Models

• BRAF(V600E)/Pten(−/−) syngeneic tumor graft model: Immunocompetent mouse model used to study BRAF inhibition and immunotherapy combination. "BRAF inhibition leads to a significant increase in the intratumoral CD8(+) T-cell density and cytokine production, similar to the effects of BRAF inhibition in patients" (PMID: 24903021)
• ESC-GEMM platform: Rapid melanoma modeling system incorporating 12 clinically relevant genotypes from combinations of LSL-Braf(V600E) and other driver alleles (PMID: 31744817)
• BrafCA/+; Tyr-CreERT2; Ptenfl/fl: Conditional BRAF V600E activation with PTEN deletion in melanocytes; develops melanoma with ~100% penetrance
• Global pannexin 1 deletion model: Combined with BRAF/Pten melanoma; increased tumor-infiltrating lymphocytes (PMID: 38327091)
• Syngeneic models: Enable immunotherapy studies; BP (BRAF V600E/PTEN−/−) model widely used

Zebrafish Models

• Tg(mitfa:BRAF(V600E)); p53(−/−): Develops melanoma from nevi over months; relatively low mutation burden
• Allows visualization of melanoma development in vivo
• "Melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process" (PMID: 24148783)
• Recurrent amplification of protein kinase A pathway in cooperation with BRAF(V600E) and p53−/−

Cell Line Models

• A375: Human melanoma cell line, BRAF V600E mutant; most widely used in vitro model
• SK-MEL-28: Human melanoma cell line, BRAF V600E
• SK-MEL-3: Used for xenograft studies of drug resistance (PMID: 41935307)
• WM266-4, Colo829: Additional BRAF V600E lines
• Drug-resistant derivatives generated for resistance mechanism studies

Model Limitations

• Mouse models may not fully recapitulate human tumor microenvironment complexity
• Syngeneic models use murine tumors that may differ in antigen presentation
• Zebrafish lack certain mammalian immune cell populations
• Cell lines may diverge from primary tumor biology after prolonged culture
• Patient-derived xenografts (PDX) better represent heterogeneity but require immunodeficient hosts

CNS Tumor Models

• Challenges in modeling heterogeneous BRAF-mutant CNS neoplasms; pediatric cancer model development lags behind adult (PMID: 37920169)

Key Findings (Evidence Summary)

Finding 1: BRAF V600E Is the Dominant Oncogenic Mutation in ~40–50% of Cutaneous Melanomas

BRAF V600E is the most frequent oncogenic BRAF mutation in melanoma, present in 40–50% of all cutaneous melanomas. Among BRAF V600 mutations specifically, V600E accounts for ~79%, V600K for ~12%, V600R for ~5%, and V600M for ~4%. The V600E substitution results in a constitutively active kinase domain with ~500-fold increased activity, leading to MAPK/ERK pathway hyperactivation independent of extracellular stimuli, driving cell proliferation, survival, angiogenesis, and other hallmark cancer features.

Key citations: - "As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E)" — PMID: 33801689 - "V600E mutation results in a constitutively active kinase domain, leading to dysregulated downstream signaling independent of extracellular stimuli" — PMID: 39961465 - "Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively" — PMID: 22536370

Finding 2: BRAF V600 Melanoma Is Associated with Younger Age, Intermittent Sun Exposure, and Trunk Location

BRAF mutations are significantly associated with distinct clinicopathological features: male gender (OR = 2.4), younger age (OR = 2.7), superficial spreading melanoma (OR = 15.6), nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6). Indoor tanning users, especially those initiating before age 25, had dramatically higher BRAF V600E prevalence (62.2% vs 31.1%, P = .003).

Key citations: - "Associations with BRAF mutation were as follows: male gender [OR = 2.4], younger age (OR = 2.7), superficial spreading (OR = 15.6) and nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)" — PMID: 25357015 - "BRAF V600E genotype was more prevalent in ever-users than in nonusers (42.9% vs 28.3%, P = .04)" — PMID: 30923800

Finding 3: BRAF+MEK Inhibitor Combination Achieves ~60% ORR but Resistance Develops Within 6–12 Months

The combination of BRAF and MEK inhibitors achieves high initial response rates (~57–70% ORR) but acquired resistance typically develops within 6–12 months. Long-term data from COMBI-d showed 3-year PFS of 22% and 3-year OS of 44% with dabrafenib + trametinib. Resistance mechanisms involve MAPK reactivation through secondary NRAS Q61 mutations, MEK1 mutations (Q56P, E203K), BRAF amplification, and alternative pathway activation.

Key citations: - "3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively" — PMID: 28475671 - "Acquired resistance to vemurafenib associated with reactivation of MAPK signaling...and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations" — PMID: 23569304

Finding 4: BRAF V600E Drives Metabolic Reprogramming; Inhibition Reverses the Shift

BRAF V600E mutations augment glycolysis (Warburg effect) to support macromolecular synthesis and proliferation, while suppressing MITF and PGC1α expression to reduce mitochondrial biogenesis. BRAF inhibition reverses this metabolic program, shifting cells toward oxidative phosphorylation — a metabolic plasticity that contributes to drug resistance.

Key citations: - "BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation" — PMID: 38972133 - "BRAF(V600E) acts to suppress expression of MITF and PGC1α. Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming and elevates OXPHOS through increased MITF-PGC1α levels" — PMID: 24610826

Finding 5: Global Melanoma Epidemiology

GLOBOCAN 2020 reported 325,000 new melanoma cases and 57,000 deaths worldwide, with highest incidence in Australia/New Zealand (males 42/100,000; females 31/100,000). BRAF V600 mutations represent 40–50% of these cutaneous melanomas.

Key citations: - "A worldwide total of 325,000 new melanoma cases (174,000 males, 151,000 females) and 57,000 deaths (32,000 males, 25,000 females) was estimated for 2020" — PMID: 35353115 - "Cutaneous melanoma causes 55,500 deaths annually" — PMID: 30238891

Mechanistic Model

The following causal chain describes the pathogenesis of BRAF V600 Mutant Melanoma:

UV Radiation (intermittent) + Genetic Susceptibility (MC1R, CDKN2A, fair skin)
    │
    ▼
    Somatic BRAF V600E Mutation in Melanocyte
    │
    ▼
    Constitutive BRAF Kinase Activation (~500x)
    │
    ├──► MEK1/2 Phosphorylation ──► ERK1/2 Activation
    │         │
    │         ├──► Cell Proliferation (Cyclin D1, c-Myc)
    │         ├──► Survival (BIM suppression, MCL-1 upregulation)
    │         ├──► Angiogenesis (VEGF)
    │         └──► Immune Evasion (PD-L1, IL-10)
    │
    ├──► MITF/PGC1α Suppression ──► Metabolic Shift to Glycolysis
    │
    └──► Cooperating Events (PTEN loss, CDKN2A deletion, TERT activation)
        │
        ▼
 Melanoma Development & Progression
        │
    ┌───────────┴───────────┐
    ▼                       ▼
    Local Invasion              Metastasis
    (Breslow depth)        (LN → Distant organs)
                    │
                    ▼
            BRAF/MEK Inhibitor Therapy
                    │
        ┌───────────┴───────────┐
        ▼                       ▼
Initial Response           Acquired Resistance
(ORR ~60-70%)         (6-12 months median)
                            │
        ┌───────────────────┼───────────────────┐
        ▼                   ▼                   ▼
MAPK Reactivation    PI3K/AKT/FAK         Metabolic Shift
(NRAS, MEK mut,      Activation            (Glycolysis → OXPHOS)
 BRAF amplification)

Evidence Base

Limitations and Knowledge Gaps

1. Optimal treatment sequencing: The ideal order of targeted therapy vs. immunotherapy for BRAF V600-mutant melanoma remains unclear; no head-to-head randomized trial comparing first-line BRAF/MEKi vs. anti-PD-1 vs. combination immunotherapy has been completed.

2. Resistance prediction: While mechanisms of acquired resistance are increasingly understood, reliable predictive biomarkers to identify patients who will develop resistance early vs. achieve durable responses are lacking.

3. Rare BRAF variants: Treatment evidence for V600R, V600M, V600D, and non-V600 BRAF mutations is limited to retrospective analyses. ORR for rare V600 non-E/K mutations is 45% vs 26% for non-V600 mutations (P = 0.025) (PMID: 40850313).

4. Ethnic diversity: Most clinical trial data come from predominantly Caucasian populations. BRAF mutation rates and responses may differ in Asian, African, and other populations. A Chinese study found mutation rates of ~50% in cutaneous but only 10–15% in acral/mucosal subtypes (PMID: 37016119).

5. Long-term survivorship: As patients increasingly achieve long-term responses, the chronic effects of prolonged targeted therapy and immunotherapy on quality of life, organ function, and secondary malignancy risk require further study.

6. Brain metastases: While intracranial activity has been demonstrated, brain metastases remain a major prognostic challenge and the optimal management (systemic therapy, SRS, WBRT, or combinations) requires further prospective data.

7. Minimal residual disease: ctDNA-guided interventional strategies (escalating therapy in ctDNA-positive patients, de-escalating in ctDNA-negative) are promising but unvalidated in prospective trials.

8. Gene-environment interactions: The precise molecular mechanism by which intermittent UV exposure preferentially induces BRAF V600E mutations (vs. other mutation patterns) is not fully elucidated.

Proposed Follow-up Experiments/Actions

1. Prospective biomarker-guided clinical trials: Design trials using baseline ctDNA and immune gene signatures to stratify patients to optimal first-line therapy (targeted vs. immunotherapy vs. combination).

2. ctDNA-guided adjuvant therapy: Test whether ctDNA-driven escalation/de-escalation strategies improve outcomes in resected stage III BRAF-mutant melanoma.

3. Novel combination strategies: Evaluate PHI-501 (pan-RAF/DDR inhibitor) and avutometinib + FAK inhibitor combinations in BRAF/MEK inhibitor-resistant patients.

4. Metabolic vulnerability exploitation: Clinical trials combining BRAF/MEK inhibitors with metabolic inhibitors (e.g., OXPHOS inhibitors, glutaminase inhibitors) to prevent metabolic adaptation-based resistance.

5. Rare BRAF variant registry: Continue global data collection through resources like the Heidelberg rare BRAF mutations database to establish evidence-based treatment guidelines for V600R, V600M, V600D, and non-V600 mutations.

6. Single-cell and spatial transcriptomics: Apply advanced technologies to resistant tumors to understand the spatial organization of resistant clones and immune microenvironment changes.

7. Diverse population studies: Conduct BRAF mutation screening and treatment outcome studies in underrepresented populations (African, Asian, Latin American) to ensure equitable access to precision medicine.

8. Brain metastasis prevention: Investigate whether early use of brain-penetrant BRAF/MEK inhibitors (e.g., encorafenib) can prevent or delay brain metastasis development in high-risk patients.

Report generated: 2026-05-05 Based on analysis of 109 published papers and 5 confirmed findings Disease: BRAF V600 Mutant Melanoma (MONDO:0005012 subtype)